GDBYF: AI 评分 61/100 — AI 分析 (4月 2026)

Goodbody Health Inc. operates in the health and wellness sector, focusing on cannabinoid (CBD) products and services within the UK and EU. The company is vertically integrated, with interests spanning from CBD extraction to retail sales and medicinal cannabis research.

Key Facts: AI Score: 61/100 Sector: Healthcare

公司概况

概要：

Goodbody Health Inc. is a UK-focused wellness company operating as a vertically integrated cannabinoid (CBD) business. Their activities encompass CBD extraction, wholesale, retail, and research. With a presence in the UK and EU, Goodbody Health also has interests in COVID and blood testing, positioning them in the specialty drug and wellness market.

GDBYF是做什么的？

Goodbody Health Inc., formerly Sativa Wellness Group Inc., is a wellness company providing a range of health and wellness products and services in the United Kingdom. Founded with a vision to capitalize on the burgeoning CBD market, the company has evolved into a vertically integrated cannabinoid business operating in both the UK and the European Union. Goodbody Health's operations span multiple segments of the CBD value chain, including CBD extraction, wholesale bulk isolate and distillate sales, retail CBD product sales, and white label sales. Additionally, the company has interests in COVID and blood testing clinics, reflecting a diversification strategy within the broader healthcare sector. Goodbody Health also engages in cannabinoid laboratory testing and medicinal cannabis research programs. The company's headquarters are located in Vancouver, Canada, while its primary operational focus remains in the UK and EU markets. The rebranding from Sativa Wellness Group Inc. to Goodbody Health Inc. in January 2022 signifies a strategic shift towards a more comprehensive health and wellness focus.

GDBYF的投资论点是什么？

Goodbody Health Inc. presents a speculative investment opportunity within the evolving CBD market in the UK and EU. The company's vertical integration offers potential for margin control and supply chain efficiencies. However, the company's negative profit margin of -13.6% indicates challenges in achieving profitability. Growth catalysts include expansion of their retail CBD offerings and progress in medicinal cannabis research programs. Key risks include regulatory uncertainties surrounding the CBD market and competition from established players. Investors should carefully consider the company's financial performance and the volatile nature of the CBD industry before investing. The high beta of 9.86 suggests significant price volatility relative to the market.

GDBYF在哪个行业运营？

Goodbody Health operates within the rapidly evolving specialty and generic drug manufacturing industry, specifically focusing on the cannabinoid (CBD) market. The global CBD market is experiencing significant growth, driven by increasing consumer awareness and acceptance of CBD products for various health and wellness applications. However, the industry is also characterized by regulatory uncertainty and intense competition. Goodbody Health's vertical integration strategy aims to provide a competitive advantage in this dynamic landscape. The company's involvement in COVID and blood testing clinics further diversifies its revenue streams within the broader healthcare sector.

Drug Manufacturers - Specialty & Generic

Healthcare

GDBYF有哪些增长机遇？

Expansion of Retail CBD Offerings: Goodbody Health can expand its retail CBD product line to cater to a broader range of consumer needs and preferences. The global CBD market is projected to reach billions of dollars in the coming years, offering significant growth potential for companies with strong retail presence and brand recognition. Timeline: Ongoing, with continuous product development and marketing efforts.
Development of Medicinal Cannabis Research Programs: Investing in medicinal cannabis research programs can lead to the development of novel therapies and intellectual property, positioning Goodbody Health to capitalize on potential regulatory changes and market expansion in the medicinal cannabis sector. The market for medicinal cannabis is expected to grow significantly as more countries legalize and regulate its use. Timeline: Medium-term, with research and development efforts spanning several years.
Geographic Expansion within the EU: Expanding its operations to other EU countries can provide access to new markets and customer bases, driving revenue growth and diversification. The European CBD market is fragmented, with varying regulatory frameworks across different countries, presenting both opportunities and challenges for expansion. Timeline: Medium-term, with market research and regulatory compliance efforts required.
Strategic Partnerships and Acquisitions: Forming strategic partnerships with other companies in the healthcare and wellness sectors can provide access to new technologies, distribution channels, and customer segments. Acquisitions of complementary businesses can further expand Goodbody Health's product portfolio and market reach. Timeline: Ongoing, with continuous evaluation of potential partnership and acquisition opportunities.
White Label and Wholesale Expansion: Increasing white label and wholesale sales of CBD isolate and distillate can provide a stable revenue stream and leverage the company's extraction capabilities. The demand for high-quality CBD ingredients is growing among manufacturers of CBD-infused products, creating opportunities for Goodbody Health to expand its wholesale business. Timeline: Ongoing, with sales and marketing efforts targeting potential white label and wholesale customers.

Vertically integrated cannabinoid (CBD) business operating in the UK and EU, providing control over the supply chain from extraction to retail sales.
Involvement in COVID and blood testing clinics, diversifying revenue streams beyond CBD products.
Gross margin of 52.4% indicates potential for profitability if operating expenses can be managed effectively.
Active in medicinal cannabis research programs, positioning the company to capitalize on potential regulatory changes and market expansion.
Headquartered in Vancouver, Canada, but primarily focused on the UK and EU markets, providing exposure to international growth opportunities.

GDBYF提供哪些产品和服务？

Provides health and wellness products and services in the United Kingdom.
Operates as a vertically integrated cannabinoid (CBD) company.
Engages in CBD extraction and wholesale bulk isolate and distillate sales.
Sells retail CBD products and offers white label sales.
Conducts cannabinoid laboratory testing.
Participates in medicinal cannabis research programs.
Operates COVID and blood testing clinics.

GDBYF如何赚钱？

Generates revenue through the sale of CBD products in retail channels.
Earns revenue from wholesale sales of CBD isolate and distillate to other manufacturers.
Provides white label CBD products to other companies for resale under their own brands.
Offers COVID and blood testing services through its clinics.

Individual consumers seeking health and wellness products, particularly CBD-based products.
Other companies in the health and wellness industry that purchase CBD isolate and distillate for use in their own products.
Businesses that require white label CBD products for resale under their own brands.
Individuals seeking COVID and blood testing services.

Vertical Integration: Controlling the entire CBD supply chain from extraction to retail provides cost advantages and quality control.
Established Presence in the UK and EU: Having an existing operational footprint in these markets provides a competitive advantage over new entrants.
Diversified Revenue Streams: Involvement in COVID and blood testing clinics diversifies revenue beyond CBD products.
Medicinal Cannabis Research Programs: Investing in research can lead to proprietary formulations and intellectual property.

什么因素可能推动GDBYF股价上涨？

Upcoming: Potential regulatory changes in the UK and EU regarding CBD and cannabis products could significantly impact the company's market access and growth prospects.
Ongoing: Expansion of the company's retail CBD product line and market reach.
Ongoing: Progress in medicinal cannabis research programs and potential development of novel therapies.
Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market access.

GDBYF的主要风险是什么？

Potential: Regulatory uncertainties surrounding the CBD market in the UK and EU could negatively impact the company's operations and financial performance.
Ongoing: Intense competition in the CBD market from established players and new entrants.
Potential: Fluctuations in raw material prices could affect the company's gross margins.
Ongoing: The company's negative profit margin (-13.6%) poses a risk to its long-term financial sustainability.
Potential: Changes in consumer preferences and trends could impact demand for the company's products.

GDBYF的核心优势是什么？

Vertically integrated CBD business model.
Presence in the UK and EU markets.
Diversified revenue streams with COVID and blood testing clinics.
Involvement in medicinal cannabis research programs.

GDBYF的劣势是什么？

Negative profit margin (-13.6%).
Reliance on the evolving and uncertain CBD market.
Limited brand recognition compared to larger competitors.
Potential regulatory challenges in the CBD and cannabis industries.

GDBYF有哪些机遇？

Expansion of retail CBD product offerings.
Geographic expansion within the EU.
Development of novel therapies through medicinal cannabis research.
Strategic partnerships and acquisitions.

GDBYF面临哪些威胁？

Intense competition in the CBD market.
Regulatory changes and uncertainties.
Fluctuations in raw material prices.
Changing consumer preferences and trends.

GDBYF的竞争对手是谁？

Accera, Inc. — Focuses on neurodegenerative diseases. — (ACCA)
Acorda Therapeutics Inc. — Develops therapies for neurological disorders. — (ACORQ)
Canopy Growth Corp — One of the largest cannabis companies. — (CBDHF)
China Commercial Credit, Inc. — Financial services company. — (CHCR)
Geno — Biotechnology company focused on sustainable materials. — (GENN)

Key Metrics

MoonshotScore: 61/100

Company Profile

CEO: Geremy Howard Prance Thomas
Headquarters: Vancouver, CA
Founded: 2019

AI Insight

AI analysis pending for GDBYF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Goodbody Health Limited do?

Goodbody Health Inc. is a wellness company operating as a vertically integrated cannabinoid (CBD) business in the UK and EU. The company's activities encompass CBD extraction, wholesale bulk isolate and distillate sales, retail CBD product sales, and white label sales. Additionally, Goodbody Health has interests in COVID and blood testing clinics, reflecting a diversification strategy within the broader healthcare sector. The company also engages in cannabinoid laboratory testing and medicinal cannabis research programs, positioning itself to capitalize on potential regulatory changes and market expansion in the medicinal cannabis sector.

What do analysts say about GDBYF stock?

As of 2026-03-16, there is no readily available analyst coverage for Goodbody Health Inc. (GDBYF) due to its OTC listing and relatively small market capitalization. Investors should conduct their own thorough research and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics, such as the P/E ratio (-0.00), should be interpreted with caution given the company's negative profitability. The high beta of 9.86 suggests significant price volatility.

What are the main risks for GDBYF?

The main risks for Goodbody Health Inc. include regulatory uncertainties surrounding the CBD market in the UK and EU, intense competition from established players and new entrants, fluctuations in raw material prices, and the company's negative profit margin. Additionally, the company's OTC listing exposes investors to risks associated with limited financial disclosure, low liquidity, and potential information asymmetry. Investors should carefully consider these risks before investing in GDBYF.